Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species
- 31 December 2003
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (12) , 3173-3189
- https://doi.org/10.1016/s0149-2918(03)90101-9
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Methods for Estimating Private Sector Payments for VA Acute Inpatient StaysMedical Care, 2003
- Linezolid versus Vancomycin for the Treatment of Methicillin‐ResistantStaphylococcus aureusInfectionsClinical Infectious Diseases, 2002
- Nurse-Staffing Levels and the Quality of Care in HospitalsNew England Journal of Medicine, 2002
- Catheter‐Related Bloodstream Infections in HIV‐Infected PatientsAnnals of the New York Academy of Sciences, 2001
- Modeling for Health Care and Other Policy Decisions: Uses, Roles, and ValidityValue in Health, 2001
- Methicillin-ResistantStaphylococcus aureusin the Community: New Battlefronts, or Are the Battles Lost?Infection Control & Hospital Epidemiology, 2000
- The Economic Impact of Staphylococcus aureus Infection in New York City HospitalsEmerging Infectious Diseases, 1999
- Intravenous-to-oral antibiotic switch therapyPostgraduate Medicine, 1997
- Nosocomial and Community-Acquired Staphylococcus aureus Bacteremias from 1980 to 1993: Impact of Intravascular Devices and Methicillin ResistanceClinical Infectious Diseases, 1996
- Consequences of Intravascular Catheter SepsisClinical Infectious Diseases, 1993